Stentys touts study data showing that its self-apposing drug-eluting stent has merit as a treatment for the booming peripheral artery disease market.
Stentys is touting clinical trial data backing the use of a drug-eluting version of its self-apposing stent for an indication beyond heart attacks: The booming peripheral artery disease market.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1zwDSjS
Cap comentari:
Publica un comentari a l'entrada